Crowdonomics
All companies

Kurve Therapeutics, Inc.

Operating

Biotech · Lynnwood, WA

Estimated pre-money ⓘ
$291.8M
As of May 2022 · from Reg A Offering (2022) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$0
Across 1 round since 2022
Latest share price
$5.80
Reg A Offering (2022) offering price

Financials

FY2021 · from SEC filings · hover any figure for its source
$71K
−$65K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021 audited
Income statement
Revenue
$70,700
Cost of goods sold
$128,344
Gross margin
-82%
Net income
-$65,427
Balance sheet
Cash
$373,804
Accounts receivable
$15,000
Total assets
$640,574
Long-term debt
$507,500
Total liabilities
$606,726
Other
Headcount
1

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$291.8M
est. pre-money
Reg A+ · Equity · May 2022

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Jul 29, 2022
ClassOutstandingVotes / shareShare of totalLast price
Common Stock50,308,155—100.0%—

Principal holders% as the filing states it, Jul 29, 2022

  • Marc Giroux1 Common Stock82.9%of company
  • Everyone else (not named in filings)17.1%

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $0 / $42.4MEst. pre-money $291.8M

Team

2 people
Marc Giroux
Director
Thomas McDowell
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

SEC filings

  • Form 1-SASep 29, 20220001929818-22-000011
    EDGAR
  • Form QUALIFAug 3, 20229999999994-22-000292
    EDGAR
  • Form 1-A/AJul 29, 20220001930260-22-000003
    EDGAR
  • Form 1-AMay 27, 20220001930260-22-000001
    EDGAR
Source: SEC EDGARCIK 0001930260DEShare price $5.80Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.